Key result
Postpartum safety of DOACs regarding abnormal uterine bleeding and cardiovascular events remains unstudied.
Why the study?
Although DOACs have largely replaced VKAs and LMWH for VTE treatment in the general population, their safety during the postpartum period had not been evaluated despite the higher risk of abnormal uterine bleeding and cardiovascular events.
Population
Postpartum patients in the French National Health Data System
Answers are grounded in this paper and cite their sources.
Should not yet alter postpartum anticoagulation practice; leaves open need for randomized safety trials.
Direct oral anticoagulants (DOACs) have largely replaced vitamin K antagonists (VKAs) and low-weight molecular heparin (LMWH) to treat venous thromboembolism (VTE) in the general population. However, safety of DOACs has not been evaluated during postpartum, despite the higher risk of abnormal uterine bleeding (AUB) and cardiovascular events in this context.
No takes yet. Share an insight, caveat, or question.
MOREUIL et al. (2026) studied this question. Direct oral anticoagulants (DOACs) have replaced VKAs and LMWH for venous thromboembolism, but their safety regarding abnormal uterine bleeding and cardiovascular events during postpartum is unstudied.
Synapse has enriched 10 related papers. Consider them for comparative context: